A Real-world Study About the Impact of Siponimod Treatment on Secondary Progressive Multiple Scle… (NCT07168694) | Clinical Trial Compass
CompletedNot Applicable
A Real-world Study About the Impact of Siponimod Treatment on Secondary Progressive Multiple Sclerosis Patients in Russia
United States606 participantsStarted 2024-04-16
Plain-language summary
The main aim of the study was to describe the demographic and clinical characteristics of patients with secondary progressive multiple sclerosis (SPMS) who were receiving siponimod therapy in Russia. This study analyzed data from outpatient records/medical records collected across 11 Russian multiple sclerosis (MS) centers. Data collection was carried out from April 16, 2024 to September 26, 2024.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria:
* Documented diagnosis of SPMS, with or without relapses.
* Treatment with siponimod for at least 6 months.
Exclusion criteria:
None.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Demographics: Number of Patients by Age
Timeframe: Baseline
2
Demographics: Number of Patients by Gender
Timeframe: Baseline
3
Time Between MS Diagnosis and Treatment Initiation
Timeframe: Baseline
4
Time Between SPMS Diagnosis and Treatment Initiation
Timeframe: Baseline
5
Time Between First Symptoms and Treatment Initiation
Timeframe: Baseline
6
Number of Patients by Clinical Characteristic Category
Timeframe: Baseline
7
Number of Patients Categorized by Type of Treatment Received Before Initiation of Siponimod